证券代码：600713.SH 证券简称：南京医药 债券代码：110098.SH 债券简称：南药转债 中信建投证券股份有限公司 关于 南京医药股份有限公司向不特定对象发行可转 换公司债券 2025 年度第三次临时受托管理事务 报告 债券受托管理人 二〇二五年六月 重要声明 本报告依据《公司债券发行与交易管理办法》（以下简称"《管理办法》"） 《公司债券受托管理人执业行为准则》《南京医药股份有限公司 2024 年向不特 定对象发行可转换公司债券之受托管理协议》（以下简称"《受托管理协议》"） 《南京医药股份有限公司向不特定对象发行可转换公司债券募集说明书》（以下 简称"《募集说明书》"）及其它相关信息披露文件以及南京医药股份有限公司（以 下简称"南京医药"、"发行人"、"上市公司"、"公司"）出具的相关说明文件和提 供的相关资料等，由受托管理人中信建投证券股份有限公司（以下简称"中信建 投证券"或"受托管理人"）编制。中信建投证券编制本报告的内容及信息均来源 南京医药提供的资料或说明。 本报告不构成对投资者进行或不进行某项行为的推荐意见，投资者应对相关 事宜做出独立判断，而不应将本报告中的任何内容据以作为中信建投 ...

Group 1 - The core viewpoint of the announcement is that Zhejiang Fulai New Materials Co., Ltd. has maintained its credit ratings for both its corporate and convertible bonds at "A+" with a stable outlook [1][2] - The previous ratings were also "A+" for both the corporate entity and the convertible bond, indicating consistency in the company's creditworthiness [1][2] - The credit rating was conducted by Zhongzheng Pengyuan Credit Rating Co., Ltd., based on a comprehensive analysis of the company's operational status and related industry conditions [2] Group 2 - The tracking credit rating report was disclosed on the Shanghai Stock Exchange website, ensuring transparency and compliance with regulatory requirements [2] - The rating assessment was last updated on June 6, 2024, reflecting the company's ongoing financial stability [1][2]

●"宏辉转债"不可作为债券质押式回购交易的质押券。 证券代码：603336 证券简称：宏辉果蔬 公告编号：2025-034 转债代码：113565 转债简称：宏辉转债 宏辉果蔬股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ●前次评级结果：公司主体信用等级为"A+"，评级展望为"稳定"；"宏 辉转债"债项信用等级为"A+"。 ●本次评级结果：公司主体信用等级为"A+"，评级展望为"稳定"；"宏 辉转债"债项信用等级为"A+"。 根据《上市公司证券发行管理办法》和《上海证券交易所股票上市规则》的 相关规定，宏辉果蔬股份有限公司（以下简称"公司"）委托信用评级机构中证 鹏元资信评估股份有限公司（以下简称"中证鹏元"）对公司于 2020 年 2 月公 开发行的 A 股可转换公司债券（简称"宏辉转债"）进行了跟踪信用评级。 宏辉转债前次评级结果：公司主体信用等级为"A+"，评级展望为"稳定"； "宏辉转债"债项信用等级为"A+"。评级机构为中证鹏元，评级时间为 2024 年 6 月 27 日。 中证 ...

Core Points - The company, Shanghai Rongtai Health Technology Co., Ltd., has maintained its credit rating of "AA-" for both its corporate and convertible bonds, with a stable outlook [1][2] - The tracking rating was conducted by Shanghai New Century Credit Rating Co., Ltd., based on a comprehensive analysis of the company's operational status and related industry [2] Group 1 - Previous bond rating was "AA-", with a stable outlook [1] - Current bond rating remains "AA-", with a stable outlook [2] - The tracking rating report was issued on June 23, 2025, and is available on the Shanghai Stock Exchange website [2]

Group 1 - The core viewpoint of the announcement is that the credit ratings for the company and its convertible bond "欧 22 转债" remain unchanged at "AA" with a stable outlook [1][2] - The previous credit rating for the company and the bond was also "AA" with a stable outlook, indicating consistency in the company's financial health [2] - The credit rating was conducted by 中证鹏元资信评估股份有限公司 based on a comprehensive analysis of the company's operational status and related industry [2] Group 2 - The announcement confirms that the credit rating results were disclosed on the same day on the Shanghai Stock Exchange website [2] - The rating assessment was last updated on June 18, 2024, and the current assessment is for the year 2025 [2]

Core Viewpoint - The company, OmniVision Integrated Circuits Group, has undergone a name change and is set to issue convertible bonds totaling RMB 2.44 billion, with a structured interest rate over six years, reflecting a strong financial performance and strategic growth in the semiconductor industry [1][8]. Section 1: Bond Issuance Details - The company has been approved to issue convertible bonds with a total face value of RMB 2.44 billion [1]. - The bonds will have a six-year term with an annual interest rate starting at 0.20% and increasing to 2.00% by the sixth year [1][5]. - The initial conversion price is set at RMB 222.83 per share, subject to adjustments based on corporate actions [1][12]. Section 2: Financial Performance - The company reported a significant increase in revenue, achieving RMB 25.73 billion in 2024, a 22.41% increase from the previous year [9][10]. - Net profit surged to RMB 332.32 million, marking a 498.11% increase year-on-year [10]. - The gross profit margin improved due to product optimization and supply chain efficiency [9]. Section 3: Use of Proceeds - The proceeds from the bond issuance will be allocated to various projects, including the expansion of wafer testing and packaging facilities, with a total investment of RMB 354.33 million [11]. - As of the end of 2024, RMB 204.22 million of the raised funds has been utilized for the intended projects [11]. Section 4: Credit Rating - The company and its bonds have received a credit rating of AA+ from Shanghai New Century Credit Rating Co., indicating a stable outlook [8][10]. Section 5: Market Position - The semiconductor industry is experiencing an upward cycle, with the company capitalizing on growth opportunities in high-end smartphone markets and automotive intelligence [9]. - The company’s semiconductor design business generated RMB 21.64 billion, accounting for 15.34% of total revenue, reflecting a 32.62% increase from the previous year [10].

（七）转股期限 本次发行的可转债转股期自可转债发行结束之日 2022 年 10 月 20 日（T+4 日）起满六个月后的第一个交易日起至可转债到期日止。债券持有人对转股或者 不转股有选择权，并于转股的次日成为公司股东。 证券代码：300984 证券简称：金沃股份 债券代码：123163 债券简称：金沃转债 浙江金沃精工股份有限公司 向不特定对象发行可转换公司债券 受托管理事务报告 （2024 年度） 债券受托管理人 二〇二五年六月 重要声明 本报告依据《公司债券发行与交易管理办法》（以下简称"《管理办法》"）、 《浙江金沃精工股份有限公司（作为发行人）与华泰联合证券有限责任公司（作 为受托管理人）关于浙江金沃精工股份有限公司向不特定对象发行可转换公司债 券之债券受托管理协议》（以下简称"《受托管理协议》"）、《浙江金沃精工股份 有限公司向不特定对象发行可转换公司债券并在创业板上市募集说明书》 （以下 《募集说明书》"）《浙江金沃精工股份有限公司 2024 年年度报告》等相关 简称" 公开信息披露文件、第三方中介机构出具的专业意见等，由本期债券受托管理人 华泰联合证券有限责任公司（以下简称"华泰联合证券"）编制 ...

Core Viewpoint - Guanglian Aviation Industry Co., Ltd. has issued convertible bonds to raise a total of RMB 700 million, with the funds primarily allocated for investment projects in the aerospace sector, despite facing a significant decline in net profit due to increased R&D expenditures and strategic adjustments in product offerings [1][22]. Section 1: Bond Overview - The company has received approval to issue 7 million convertible bonds, each with a face value of RMB 100, totaling RMB 70 million, with a net amount of RMB 69.20476 million after deducting issuance costs [1][22]. - The bonds have a maturity of 6 years, with interest rates starting at 0.30% in the first year and increasing to 3.00% by the sixth year [1][22]. - The initial conversion price is set at RMB 32.32 per share, with provisions for adjustments based on various corporate actions [1][22]. Section 2: Financial Performance - In 2024, the company reported revenue of RMB 1,048.13 million, a 41.64% increase year-on-year, but faced a net loss of RMB 49.10 million, a decline of 146.94% compared to the previous year [22]. - The company’s R&D investment reached RMB 83.14 million, a 44.55% increase, focusing on new drone platforms and other aerospace projects [22]. - The net asset value decreased by 5.55% to RMB 1,431.27 million, while total assets increased by 14.32% to RMB 4,980.98 million [22]. Section 3: Use of Proceeds - The total amount raised from the bond issuance will be used for investment projects totaling RMB 85.17 million, with the entire net proceeds allocated to these projects [22]. - The company may utilize self-raised funds for initial investments in these projects before the bond proceeds are available [22].

Core Viewpoint - Beijing Strong Biotechnologies, Inc. (referred to as "the Company") has issued convertible bonds to raise funds for its diversified and high-quality in vitro diagnostic testing platform, with a total fundraising amount of RMB 1.139 billion [3][16]. Section 1: Bond Issuance Details - The Company approved the issuance of convertible bonds on September 6, 2021, and received regulatory approval from the China Securities Regulatory Commission on June 6, 2022 [2][3]. - A total of 11.39 million convertible bonds were issued at a face value of RMB 100 each, raising a gross amount of RMB 113.9 million, with a net amount of RMB 112.685 million after deducting issuance costs [3][4]. Section 2: Financial Performance - For the fiscal year 2024, the Company reported a revenue of RMB 165,893.20 million, a decrease of 4.75% compared to RMB 174,162.67 million in 2023 [21]. - The net profit attributable to shareholders increased by 1.70% to RMB 53,263.53 million from RMB 52,374.28 million in the previous year [22]. - The total assets of the Company grew by 7.71% to RMB 557,496.52 million, while the net assets attributable to shareholders increased by 11.11% to RMB 413,837.41 million [22]. Section 3: Use of Proceeds - The net proceeds from the bond issuance will be allocated to various projects, with a total planned investment of RMB 128.9 million [16][18]. - The Company will self-finance any shortfall if the actual net proceeds are less than the planned investment amount [19]. Section 4: Bondholder Rights and Management - The bondholders have rights to interest payments, conversion to shares, and the ability to sell back their bonds under certain conditions [15][12]. - The Company has established a special account for managing the proceeds from the bond issuance, ensuring that funds are used as intended [23]. Section 5: Credit Rating - The Company has maintained a credit rating of AA- with a stable outlook from Zhongjian Pengyuan Credit Rating Co., Ltd. since November 2021 [20][27].

Group 1 - The company, Henan Jindan Lactic Acid Technology Co., Ltd, issued 7,000,000 convertible bonds with a total fundraising amount of approximately RMB 689.61 million [1][13] - The bonds have a face value of RMB 100 each and are set to be listed on the Shenzhen Stock Exchange [1][2] - The initial conversion price for the bonds is set at RMB 20.94 per share, which is based on the average trading price of the company's stock prior to the announcement [1][2] Group 2 - The company specializes in the research, production, and sales of lactic acid and its derivatives, with a production capacity of 183,000 tons per year [9][10] - The main products include lactic acid, sodium lactate, and calcium lactate, which are widely used in food, feed, biodegradable materials, and pharmaceuticals [9][10] - The company has been recognized as a leading enterprise in the lactic acid industry, exporting products to over 90 countries and regions [9][10] Group 3 - For the fiscal year 2024, the company reported a revenue of RMB 150.54 million, a year-on-year increase of 6.15%, primarily due to increased sales of lactic acid and lactate products [11] - The operating profit and net profit attributable to shareholders decreased significantly by 67.93% and 56.01% respectively, mainly due to impairment losses [11][12] - The net cash flow from operating activities increased by 634.96% to RMB 26.05 million, attributed to reduced procurement costs for corn raw materials [12] Group 4 - The company plans to use the proceeds from the convertible bonds for projects including the construction of a 75,000-ton biodegradable material project, with total project investment estimated at RMB 1.03 billion [8][15] - As of December 31, 2024, the company had utilized RMB 504.15 million of the raised funds, with the remaining funds allocated for ongoing project construction [15] - The project to produce biodegradable materials is currently under construction and is expected to reach operational status by August 2025 [15][17]